Europe is one of the world’s most significant medical technology markets, and one of its most complex. With more than 38,000 MedTech companies operating across the continent, a rigorous regulatory framework under EU MDR and IVDR, and a network of world-class research and manufacturing clusters, it represents both a major opportunity and a substantial challenge for manufacturers, diagnostics companies, and pharma organisations looking to operate here.
This guide covers what the European MedTech landscape actually looks like: where the key hubs are, what kinds of companies operate here, and what any organisation, whether entering the EU market for the first time or scaling an existing presence, needs to understand about the environment they’re entering.
The Scale of Europe’s MedTech Industry
According to MedTech Europe, the sector directly employs over 930,000 people across the continent and generates annual revenues estimated at roughly €170 billion (2024). It is one of the largest life sciences industries in the world, second only to the United States in terms of market size.
A few figures that put the landscape in context:
- 38,000+ companies: operating in medical devices, IVDs, and digital health
- Over 90% are SMEs: the sector is dominated by small and mid-sized innovators, not large multinationals
- Europe accounts for roughly 27% of global MedTech revenue
- The EU is the world’s second-largest medical device market after the US
- More than 2,000,000 medical technology products and services currently available in the European market
For US manufacturers, Asian diagnostics companies, and global pharma organisations, Europe is not a single market — it is a collection of national healthcare systems, procurement processes, and regulatory pathways that sit under a shared EU framework. Understanding where the industry is concentrated, and how it operates, is the starting point for any effective market strategy.
Europe’s Major MedTech Hubs
Germany: The Largest Market in Europe
Germany is the single largest MedTech market in Europe, accounting for roughly €40 billion in annual revenue and home to major global players including Siemens Healthineers, B. Braun, Dräger, and Karl Storz, alongside thousands of specialist mid-sized manufacturers (the Mittelstand).
Key clusters include:
- Tuttlingen (Baden-Württemberg): The surgical instruments capital of the world. Over 400 MedTech companies operate within a 20km radius, manufacturing more than half of the world’s surgical instruments.
- Munich: A hub for medical imaging, digital health, and life sciences, anchored by Siemens Healthineers and a growing startup ecosystem.
- Hamburg and the Rhine-Ruhr region: Strong in diagnostics, laboratory technology, and healthcare IT.
Germany also hosts two of Europe’s most important MedTech trade events: MEDICA in Düsseldorf (the world’s largest medical trade fair) and COMPAMED, its companion event for medical technology suppliers.
For IVD and diagnostics companies, Germany is particularly significant, it is one of the largest markets for in vitro diagnostics globally and home to companies such as Roche Diagnostics and Qiagen.
The Netherlands: Diagnostics and Digital Health Innovation
The Netherlands punches well above its weight in MedTech. Philips Healthcare is headquartered in Amsterdam and Eindhoven, and the country has developed a strong ecosystem around medical imaging, point-of-care diagnostics, and health technology.
The Brainport Eindhoven region is one of Europe’s most productive technology clusters, with Philips and ASML as anchors and a dense network of high-tech suppliers and spin-offs. Dutch MedTech companies benefit from strong R&D infrastructure, close ties between university medical centres and industry, and an internationally oriented business environment.
The Netherlands is also a significant European gateway market, its logistics infrastructure (Rotterdam port, Schiphol Airport) and the presence of major European headquarters make it a preferred entry point for non-EU manufacturers registering their first EU presence.
France: A Major Market with Growing Innovation
France is the third-largest MedTech market in Europe, with a sizeable domestic industry and a healthcare system that is one of the continent’s largest public purchasers of medical technology.
Key companies include Stryker’s European operations, Guerbet, Servier Medical, and a growing cluster of digital health and AI-powered diagnostics startups concentrated around Paris, Lyon, and Grenoble. Lyon in particular has emerged as a strong hub for minimally invasive surgery and interventional cardiology, building on the presence of bioMérieux (a global diagnostics leader headquartered nearby in Marcy-l’Étoile).
France’s national innovation agency Bpifrance and the health innovation programmes under France 2030 have significantly increased investment in digital health and MedTech startups, making it an increasingly dynamic market for early-stage companies and international partners alike.
Spain: A Fast-Growing Hub with Iberian Reach
Spain is one of Europe’s most dynamic and fast-growing MedTech markets, with a strong concentration of companies in Barcelona, Madrid, and the Basque Country. The Spanish sector has historically been strong in orthopaedics, dental technology, and hospital equipment, but it is increasingly significant in IVDs, molecular diagnostics, and digital health.
Barcelona is home to a thriving life sciences ecosystem anchored by the Barcelona Health Hub, the proximity of world-class research institutions (IRB, CRG, ISGlobal), and a growing cluster of diagnostics and genomics companies. Madrid is the commercial and regulatory centre, with strong connectivity to Latin American markets — a route often used by global manufacturers to establish a dual EU/LATAM presence.
For companies targeting the Spanish and Portuguese-speaking world, Spain also serves as a strategic gateway to Latin America, with regulatory knowledge and commercial networks that extend to Brazil, Mexico, Colombia, and beyond.
A landmark development for the Spanish regulatory environment is Royal Decree 192/2023, which introduced specific requirements for clinical investigations with medical devices and IVDs in Spain, bringing national legislation into closer alignment with EU MDR and IVDR.
United Kingdom: Post-Brexit Reconfiguration
The UK remains one of Europe’s most important MedTech markets, even outside the EU. With a market value exceeding £10 billion, the UK is home to major global players (Smith+Nephew, Oxford Instruments, Consort Medical), a world-leading academic research base, and a concentration of MedTech companies around London, Cambridge, Oxford, and the M4 corridor.
The critical development for any manufacturer is the post-Brexit regulatory divergence. The UKCA mark (UK Conformity Assessed) is now required for devices placed on the Great Britain market, separate from the EU CE mark. While the UK has extended the period during which CE-marked devices can be sold in Great Britain, the timelines for full UKCA compliance are firm and require planning.
The MHRA (Medicines and Healthcare products Regulatory Agency) has been active in shaping post-Brexit regulatory guidance, and the UK has also signalled ambitions to develop faster, innovation-friendly pathways — including the ILAP (Innovative Licensing and Access Pathway) for combination products.
For manufacturers already CE-marked, the UK requires a separate regulatory strategy. For those entering from outside Europe, the question of CE + UKCA sequencing is an important early strategic decision.
Switzerland: Precision and High-Value Manufacturing
Switzerland is not an EU member but operates under a mutual recognition agreement for medical devices and is deeply integrated into the European MedTech ecosystem. It is home to some of the world’s most significant MedTech and diagnostics companies: Roche (Basel), Novartis (Basel), Straumann (dental), Ypsomed (drug delivery), and a dense cluster of precision manufacturing suppliers in the watch-making tradition that has transferred into surgical robotics, implants, and microfluidics.
Switzerland’s combination of engineering excellence, multilingual workforce, and proximity to major EU markets makes it a significant hub for high-value device development and manufacturing, and a frequent base for global companies establishing their European regulatory presence.
The Regulatory Landscape: What It Means in Practice
Understanding the MedTech industry in Europe is inseparable from understanding its regulatory framework. The introduction of EU MDR (2017/745) and EU IVDR (2017/746) represents the most significant overhaul of European medical device regulation in 25 years, and it has reshaped how companies of all sizes operate.
For manufacturers entering the EU market for the first time, the key requirements include:
- CE marking through a conformity assessment route appropriate to the device’s risk classification
- Technical documentation demonstrating safety and performance, including clinical evidence
- Quality Management System (QMS) certified to ISO 13485
- EUDAMED registration, the EU’s centralised database for devices, manufacturers, and clinical investigations, which becomes mandatory from May 2026
- Notified Body involvement for Class IIa, IIb, III (MD) and Class B, C, D (IVD) devices
- EU Authorised Representative (EU AR) for manufacturers based outside the EU
For IVD and diagnostics companies specifically, IVDR introduced a significant reclassification of products — the vast majority of IVDs that were previously self-certified under the old IVDD now require Notified Body review under IVDR, including companion diagnostics, oncology markers, and infectious disease assays. The transition timelines vary by device class and certification status.
For pharma companies developing companion diagnostics, the EU framework requires co-development alignment between the drug and its accompanying IVD, with specific submission pathways for Class D companion diagnostics (EMA consultation required).
Opportunities in the European MedTech Market
Despite, and in some ways because of, its regulatory complexity, Europe offers compelling opportunities for manufacturers and diagnostics companies with the right preparation.
Market access across 27 EU member states through a single CE mark remains one of the most powerful aspects of the European regulatory system. A device approved in Germany can be sold in France, Spain, Italy, Poland, and beyond without separate national approvals in most cases.
The SME ecosystem creates partnership opportunities. With over 90% of European MedTech companies being SMEs, there is a substantial market for contract research, regulatory outsourcing, clinical study support, and quality management services — particularly as regulatory demands increase under MDR and IVDR.
Growing demand in IVDs and molecular diagnostics is accelerating across Europe, driven by population ageing, oncology precision medicine, and the lessons of COVID-19 for diagnostic infrastructure. Countries including Spain, Portugal, Germany, and the Netherlands are investing significantly in laboratory infrastructure and point-of-care testing capacity.
The Spanish and Portuguese-speaking corridor (Spain, Portugal, and by extension Latin America) represents a particularly underexploited route for companies seeking both EU certification and access to a combined market of over 600 million people. Regulatory expertise that spans the EU and LATAM is rare and commercially valuable.
What Companies Operating in Europe Need to Get Right
Three things consistently determine whether a MedTech company navigates the European environment successfully:
1. Regulatory strategy from day one. The classification of a device under MDR or IVDR determines the entire development and approval pathway. Getting this wrong early, misclassifying a device, choosing the wrong conformity assessment route, or underestimating the clinical evidence requirements, creates delays that are expensive and difficult to recover from.
2. Clinical evidence that meets the standard. Both MDR and IVDR have raised the bar for clinical evidence significantly. For medical devices, clinical evaluation is an ongoing process, not a one-time submission. For IVDs, performance evaluation under ISO 20916 must be designed to satisfy both EU and, where applicable, FDA requirements.
3. A Notified Body relationship that works. With only a limited number of IVDR-designated Notified Bodies currently active, access to conformity assessment is a genuine constraint. Early engagement, well-prepared technical documentation, and experience managing the review process are not optional, they are the difference between a smooth approval and a two-year delay.
About MDx CRO
MDx CRO is a full-service MedTech CRO specialising in clinical research, regulatory affairs, and technical documentation for medical devices and IVDs. With offices in Barcelona, Madrid, Lisbon, and London, and a team operating across Europe, MDx supports manufacturers, diagnostics companies, and pharma organisations at every stage, from early regulatory strategy to Notified Body submission and post-market compliance.
Explore our services or get in touch to discuss your European regulatory and clinical strategy.
We partner with both large diagnostic leaders and agile SMEs to deliver compliant, high-quality, and market-ready solutions.
A Pan-European Presence
With offices in Barcelona, Madrid, Lisbon, and London, and a network of CRAs and regulatory experts across Europe, MDx provides localized insight with global reach—helping MedTech companies meet requirements faster and smarter.
The European MedTech sector is growing—but so are its regulatory challenges. Whether you’re launching a new diagnostic product or preparing for a Notified Body audit, MDx CRO is here to support your success every step of the way.
Let’s talk about your next clinical or regulatory challenge.
Further Reading
